NIH Grants Biotech Firm Monopoly on Cutting-Edge Cancer Detection Tech
Published Date: 11/19/2025
Notice
Summary
The National Institutes of Health plans to give BioncoDx, LLC an exclusive license to use special methods for diagnosing and predicting cancer. This means BioncoDx will have the sole right to develop and sell these cancer-related technologies. If you want to comment or apply for a license, you need to act by December 4, 2025.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Exclusive Urine-Based Cancer Test License
The NIH plans to grant BioncoDx, LLC an exclusive license to develop, manufacture, and commercialize Food and Drug Administration (FDA) premarket approval tests that use four urine biomarkers—creatine riboside, metabolite 561+, cortisol sulfate, and N-acetylneuraminic acid—to detect and prognose cancers (examples listed include lung, breast, colorectal, kidney/bladder, prostate, liver, stomach, pancreatic, GYN, and brain). The notice describes this technology as a unique, non-invasive screening and diagnostic tool that can detect cancers at an early stage using urine samples and that urine sampling minimizes patient discomfort compared with invasive methods.
Sole Commercial Rights for BioncoDx
The prospective license would give BioncoDx the sole (exclusive) right to practice the listed patent rights worldwide where patent rights exist for the specified field of use: developing, manufacturing, and commercializing FDA PMA tests using the named biomarkers for screening/diagnosing the listed cancers. After a negotiated period, the exclusive field of use will be reduced to a subset of three cancer indications and will include strict developmental benchmarks for each indication.
Prospective License Will Be Royalty‑Bearing
The notice states the prospective exclusive license will be royalty-bearing. The notice also states that the license may be granted unless, within fifteen (15) days from the date of the published notice, the National Cancer Institute receives written evidence and argument that the grant would not be consistent with applicable law.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-20289, Recertification of Cook Inlet Regional Citizens' Advisory Council
The Coast Guard has officially renewed the Cook Inlet Regional Citizens' Advisory Council (CIRCAC) for another year, from September 1, 2025, to August 31, 2026. This group keeps an eye on oil activities in Cook Inlet, Alaska, and since there were no big changes in their latest application, their recertification was smooth and quick. Local communities and environmental watchers can keep counting on CIRCAC’s watchful role without any new fees or delays.
Next: 2025-20291, Agency Information Collection Activities: Comment Request on Burden Related to Superfund; Imported Substances; Procedures for Filing a Petition
The IRS wants your thoughts on how hard it is to ask if certain imported substances should be taxed or not under Superfund rules. This affects businesses dealing with these substances and could change how paperwork is handled, possibly saving time and money. Make sure to send your comments by January 20, 2026, to help shape the process!